Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV.
Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, Metcalf JA, Sereti I, Polis MA, Davey RT, Tavel J, Falloon J, Stevens R, Lambert L, Dewar R, Schwartzentruber DJ, Anver MR, Baseler MW, Masur H, Dimitrov DS, Lane HC. Kovacs JA, et al. Among authors: tavel j. J Exp Med. 2001 Dec 17;194(12):1731-41. doi: 10.1084/jem.194.12.1731. J Exp Med. 2001. PMID: 11748275 Free PMC article.
Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients.
Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, Sachau W, Kelly G, Metcalf JA, Davey RT Jr, Falloon J, Polis MA, Tavel J, Stevens R, Lambert L, Hosack DA, Bosche M, Issaq HJ, Fox SD, Leitman S, Baseler MW, Masur H, Di Mascio M, Dimitrov DS, Lane HC. Kovacs JA, et al. Among authors: tavel j. J Clin Invest. 2005 Aug;115(8):2139-48. doi: 10.1172/JCI23196. Epub 2005 Jul 14. J Clin Invest. 2005. PMID: 16025158 Free PMC article.
A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
Tavel JA, Sereti I, Walker RE, Hahn B, Kovacs JA, Jagannatha S, Davey RT Jr, Falloon J, Polis MA, Masur H, Metcalf JA, Stevens R, Rupert A, Baseler M, Lane HC. Tavel JA, et al. J Infect Dis. 2003 Aug 15;188(4):531-6. doi: 10.1086/377285. Epub 2003 Jul 31. J Infect Dis. 2003. PMID: 12898439 Clinical Trial.
Interferon-alpha produces significant decreases in HIV load.
Tavel JA, Huang CY, Shen J, Metcalf JA, Dewar R, Shah A, Vasudevachari MB, Follmann DA, Herpin B, Davey RT, Polis MA, Kovacs J, Masur H, Lane HC. Tavel JA, et al. J Interferon Cytokine Res. 2010 Jul;30(7):461-4. doi: 10.1089/jir.2009.0090. J Interferon Cytokine Res. 2010. PMID: 20235638 Free PMC article. Clinical Trial.
Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals.
Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, Bechtel C, Herpin B, Muul L, Zheng Z, Jagannatha S, Bunnell BA, Fellowes V, Metcalf JA, Stevens R, Baseler M, Leitman SF, Read EJ, Blaese RM, Lane HC. Morgan RA, et al. Among authors: tavel ja. Hum Gene Ther. 2005 Sep;16(9):1065-74. doi: 10.1089/hum.2005.16.1065. Hum Gene Ther. 2005. PMID: 16149905
CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients.
Read SW, Lempicki RA, Di Mascio M, Srinivasula S, Burke R, Sachau W, Bosche M, Adelsberger JW, Sereti I, Davey RT Jr, Tavel JA, Huang CY, Issaq HJ, Fox SD, Lane H, Kovacs JA. Read SW, et al. Among authors: tavel ja. J Infect Dis. 2008 Sep 15;198(6):843-50. doi: 10.1086/591250. J Infect Dis. 2008. PMID: 18684102 Free PMC article.
50 results